ProfileGDS5678 / 1426201_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 55% 54% 54% 55% 53% 56% 54% 54% 54% 54% 54% 54% 54% 54% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4250955
GSM967853U87-EV human glioblastoma xenograft - Control 23.3474154
GSM967854U87-EV human glioblastoma xenograft - Control 33.3484254
GSM967855U87-EV human glioblastoma xenograft - Control 43.3023755
GSM967856U87-EV human glioblastoma xenograft - Control 53.2587453
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.5070256
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.4043854
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3127154
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3011954
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.3126554
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.333354
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.2846854
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.3448254
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.3378154